Pathophysiological and clinical aspects of malnutrition in chronic renal failure

Nutrition Research Reviews

Volumn 18, Issue 1, 2005, Pages 89-97

  Caimi, Gregorio ^a,b   Carollo, C ^b   Presti, R Lo ^b  

^a Università di Palermo ^*  (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Atherosclerosis; Chronic renal failure; Kidney disease; Malnutrition

Indexed keywords

AMINO ACID; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CARNITINE; CATHEPSIN D; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 1; INTERLEUKIN 6; IRON; LEPTIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PREALBUMIN; RETINOL BINDING PROTEIN; SERUM ALBUMIN; SOMATOMEDIN C; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; UREMIC TOXIN; VERY LOW DENSITY LIPOPROTEIN;

AMINO ACID METABOLISM; ANTHROPOMETRY; ATHEROSCLEROSIS; CARBAMOYLATION; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC INFLAMMATION; CHRONIC KIDNEY FAILURE; COMPUTER ASSISTED TOMOGRAPHY; ENDOTHELIUM LESION; GLUCOSE METABOLISM; HEMODIALYSIS PATIENT; HUMAN; HYPOALBUMINEMIA; IMMUNE RESPONSE; IMPEDANCE; INSULIN CLEARANCE; INSULIN RELEASE; INSULIN RESISTANCE; IRON DEFICIENCY; IRON OVERLOAD; MALNUTRITION; METABOLIC ACIDOSIS; MORTALITY; NEUTRON ACTIVATION ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL STATUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN RESTRICTION; REVIEW; UNITED STATES; UREMIA;

EID: 20444452171     PISSN: 09544224     EISSN: None     Source Type: Journal    
DOI: 10.1079/NRR200599     Document Type: Review

References (82)

1. Allen KL, Miskulin D, Yan G, Dwyer JT, Frydrych A, Leung J, Poole D & the Hemodialysis (HEMO) Study Group (2002) Association of nutritional markers with physical and mental health status in prevalent hemodialysis patients from HEMO Study. Journal of Nutrition 12, 160-169.
2. Allison SP (2000) Malnutrition, disease, and outcome. Nutrition 16, 590-593.
3. Annuk M, Zilmer M & Fellstrom B (2003) Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: impact on cardiovascular disease. Kidney International 63, Suppl. 84, S50-S53.
4. Apeland T, Mansoor MA, Seljeflot I, Bronstad I, Goransson L & Strandjord RE (2002) Homocysteine, malondialdehyde and endothelial markers in dialysis patients during low-dose folinic acid therapy. Journal of Internal Medicine 252, 456-464.
5. Arias E, Anderson RN, Kung HC, Murphy SL & Kochanek KD (2003) Deaths: final data for 2001. National Vital Statistics Reports 52, 1-115.
6. Ates K, Ates A, Kutlay S, Nergizoglu G & Karatan O (2004) Total lymphocyte count in peripheral blood of peritoneal dialysis patients: relationship to clinical parameters and outcome. Journal of Nephrology 17, 246-252.
7. Bergstrom J (1999) Mechanisms of uremic suppression of appetite. Journal of Renal Nutrition 9, 129-132.
8. Cano N (2000) Denutrition et insuffisance renale chronique (Malnutrition and chronic renal failure). Annales de Medecine Interne 151, 563-574.
9. Carvounis CP, Manis T, Coritsidis G, Dubinsky M & Serpente P (2000) Total lymphocyte count: a promising prognostic index of mortality in patients on CAPD. Peritoneal Dialysis International 20, 33-38.
10. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, Zingraff J, Verger C, Jungers P & Descamps-Latscha B (1996) Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radical Biology and Medicine 21, 845-853.
11. Channon KM & Guzik TJ (2002) Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. Journal of Physiology and Pharmacology 53, 515-524.
12. Chauveau P, Fouque D, Combe C, Laville M, Canaud B, Azar R, Cano N, Aparicio M & Leverve X (2000) Acidosis and nutritional status in hemodialyzed patients. Seminars in Dialysis 13, 241-246.
13. Chazot C, Laurent G, Charra B, Blanc C, VoVan C, Jean G, Vanel T, Terrat JC & Ruffet M (2001) Malnutrition in long-term haemodialysis survivors. Nephrology Dialysis and Transplantation 16, 61-69.
14. Chumlea WC, Dwyer J, Bergen C, Burkart J, Paranandi L, Frydrych A, Cockram DB, Kusek JW, McLeroy S & Hemodialysis Study Group (2003) Nutritional status assessed from anthropometric measures in the HEMO study. Journal of Renal Nutrition 13, 31-38.
15. Collins AJ, Kasiske B, Herzog C, Chen SC, Everson S, Constantini E, Grimm R, McBean M, Xue J, Chavers B, Matas A, Manning W, et al. (2003) Excerpts from the United States Renal Data System 2003 annual data report: atlas of end-stage renal disease in the United States. American Journal of Kidney Diseases 42, A5-A7.
16. Dalle-Donne I, Giustarini D, Colombo R, Rossi R & Milzani A (2003) Protein carbonylation in human diseases. Trends in Molecular Medicine 9, 169-176.
17. De Precigout V, Chauveau P, Delclaux C, El Haggan W, Baillet L, Barthe N, Gobinet A, Combe C & Aparicio M (2000) No change of hyperleptinemia despite a decrease in insulin concentration in patients with chronic renal failure on a supplemented very low protein diet. Americal Journal of Kidney Diseases 36, 1201-1206.
18. Detsky AS, Baker JP, Mendelson RA, Wolman SL, Wesson DE & Jeejeebhoy KN (1984) Evaluating the accuracy of nutritional assessment techniques applied to hospitalized patients: methodology and comparisons. Journal of Parenteral and Enteral Nutrition 8, 153-159.
19. Feld S & Hirschberg R (1996) Growth hormone, the insulin-like growth factor system, and the kidney. Endocrine Reviews 17, 423-480.
20. Feneberg R, Sparber M, Veldhuis JD, Mehls O, Ritz E & Schaefer F (2002) Altered temporal organization of plasma insulin oscillations in chronic renal failure. The Journal of Clinical Endocrinology and Metabolism 87, 1965-1973.
21. Flanigan MJ, Frankenfield DL, Prowant BF, Bailie GR, Frederick PR & Rocco MV (2001) Nutritional markers during peritoneal dialysis: data from the 1998 Peritoneal Dialysis Core Indicators Study. Peritoneal Dialysis International 21, 345-354.
22. Franceschini R, Robaudo C, Corsini G, Cataldi A, Bruno E, Russo R, Rolandi E & Barreca T (1998) Somatostatin release in response to glucose is impaired in chronic renal failure. Biomedicine and Pharmacotherapy 52, 208-213.
23. Galle J, Seibold S & Wanner C (2003) Inflammation in uraemic patients: what is the link? Kidney and Blood Pressure Research 26, 65-75.
24. Galle J & Wanner C (1997) Oxidative stress and vascular injury-relevant for atherogenesis in uraemic patients? Nephrology Dialysis Transplantation 12, 2480-2483.
25. Galle J & Wanner C (1999) Modification of lipoproteins in uremia: oxidation, glycation and carbamoylation. Mineral and Electrolyte Metabolism 25, 263-268.
26. Garibotto G (1999) Muscle amino acid metabolism and the control of muscle protein turnover in patients with chronic renal failure. Nutrition 15, 145-155.
27. Garibotto G, Pastorino N & Sofia A (2001) Il controllo del metabolismo proteico nei pazienti in trattamento dialitico (The control of protein metabolism in dialysis treatment patients). Giornale Italiano di Nefrologia 18, 683-694.
28. Golden MHN (1982) Transport proteins as indices of protein status. American Journal of Clinical Nutrition 35, Suppl. 5, 1159-1165.
29. Goodship THJ (1998) What is the relationship between metabolic acidosis and nutritional status in dialysis patients? American Journal of Kidney Diseases 31, 884-889.
30. Guarnieri G, Antonione R & Biolo G (2003) Mechanisms of malnutrition in uremia. Journal of Renal Nutrition 13, 153-157.
31. Guarnieri G, Toigo G, Situlin R, Faccini L, Coli U, Landini S, Bazzato G, Dardi F & Campanacci L (1983) Muscle biopsy studies in chronically uremic patients: evidence for malnutrition. Kidney International 16, Suppl., S187-S193.
32. Haviv YS, Sharkia M & Safadi R (2000) Hypoglycemia in patients with renal failure. Renal Failure 22, 219-223.
33. Henle T (2003) AGEs in foods: do they play a role in uremia? Kidney International 63, Suppl. 84, S145-S147.
34. Himmelfarb J, Stenvinkel P, Ikizler TA & Hakim RM (2002) The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney International 62, 1524-1538.
35. Ishimura E, Okuno S, Kitatani K, Kim M, Shoji T, Nakatani T, Inaba M & Nishizawa Y (2002) Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients - importance of glycaemic control. Diabetologia 45, 1446-1448.
36. Johannsson G & Ahlmen J (2003) End-stage renal disease: endocrine aspects of treatment. Growth Hormone and IGF Research 13, Suppl. A, S94-S101.
37. Kalantar-Zadeh K, Supasyndh O, Lehn RS, McAllister CJ & Kopple JD (2003) Normalized protein nitrogen appearance is correlated with hospitalization and mortality in hemodialysis patients with Kt/V greater than 1.20. Journal of Renal Nutrition 13, 15-25.
38. Kasper M & Funk RH (2001) Age-related changes in cells and tissues due to advanced glycation end products (AGEs). Archives of Gerontology and Geriatrics 32, 233-243.
39. Kaysen GA, Dubin JA, Muller HG, Mitch WE, Resales LM & Levin NW (2002) Relationships among inflammation, nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney International 61, 2240-2249.
40. Kaysen GA & Kumar V (2003) Inflammation in ESRD: causes and potential consequences. Journal of Renal Nutrition 13, 158-160.
41. Kopple JD (1999) Pathophysiology of protein-energy wasting in chronic renal failure. Journal of Nutrition 129, Suppl. 1S, 247S-251S.
42. Kovacic V, Roguljic L & Kovacic V (2003) Metabolic acidosis of chronically hemodialyzed patients. Americal Journal of Nephrology 23, 158-164.
43. Kraus LM & Kraus AP Jr (2001) Carbamoylation of amino acids and proteins in uremia. Kidney International 59, Suppl. 78, S102-S107.
44. Leypoldt JK, Cheung AK, Carroll CE, Stannard DC, Pereira BJ, Agodoa LY & Port FK (1999) Effect of dialysis membranes and middle molecules removal on chronic hemodialysis patient survival. American Journal of Kidney Diseases 33, 349-355.
45. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C & Zoccali C (2003) Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrology Dialysis and Transplantation 18, 1272-1280.
46. Lowrie EG & Lew NL (1990) Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. American Journal of Kidney Diseases 15, 458-482.
47. Mak RHK (2000) Impact of end-stage renal disease and dialysis on glycaemic control. Seminars in Dialysis 13, 4-8.
48. Mancini A, Grandaliano G, Magarelli P & Allegretti A (2003) Nutritional status in hemodialysis patients and bioimpedance vector analysis. Journal of Renal Nutrition 13, 199-204.
49. Manno C, Gesualdo L, D'Altri C, Rossini M, Grandaliano G & Schena FP (2001) Valutazione e trattamento della malnutrizione in dialisi (Appraisal and treatment of malnutrition in dialysis patients). Giornale Italiano di Nefrologia 18, 542-551.
50. Massy ZA & Nguyen-Khoa T (2002) Oxidative stress and chronic renal failure: markers and management. Journal of Nephrology 15, 336-341.
51. Memoli B, Guida B, Saravo MT, Nastasi A, Trio R, Liberti R, D'Arcangelo R, Romano G, Esposito A & Cianciaruso B (2002) Fattori predittivi e diagnostici della malnutrizione nel paziente in trattamento emodialitico (Predictive and diagnostic factors of malnutrition in hemodialysis patients). Giornale Italiano di Nefrologia 19, 456-466.
52. Mitch WE, Du J, Bailey JL & Price SR (1999) Mechanisms causing muscle proteolysis in uremia: the influence of insulin and cytokines. Mineral and Electrolyte Metabolism 25, 216-219.
53. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, Maeda K, Kurokawa K & van Ypersele de Strihou C (1997) Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney International 51, 1170-1181.
54. Morena M, Cristol JP & Canaud B (2000) Why hemodialysis patients are in a prooxidant state? What could be done to correct the pro/antioxidant imbalance. Blood Purification 18, 191-199.
55. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Disease 39, Suppl. 1, S1-S266.
56. Nevalainen P, Lahtela JT, Mustonen J & Pasternack A (1997) The influence of peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1 diabetic patients. Nephrology Dialysis and Transplantation 12, 145-150.
57. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Drueke TB, Lacour B & Thévenin M (2001) Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrology Dialysis and Transplantation 16, 335-340.
58. Norton PA (2002) Affect of serum leptin on nutritional status in renal disease. Journal of the American Dietetic Association 102, 1119-1125.
59. Peck LW (1997) Essential fatty acid deficiency in renal failure: can supplements really help? Journal of the American Dietetic Association 97, Suppl. 2, S150-S153.
60. Pecoits-Filho R, Nordfors L, Heimburger O, Lindholm B, Anderstam B, Marchlewska A & Stenvinkel P (2002) Solubile leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. European Journal of Clinical Investigation 32, 811-817.
61. Querques M, Strippoli GF, Dell'Aquila R, Gallucci M, Di Iorio B, Manno C & Gruppo di Studio Apulo-Lucano sulla Nutrizione (2002) Prevalenza della malnutrizione negli uremici in trattamento emodialitico di Puglia e Lucania (Prevalence of malnutrition in uremic patients undergoing hemodialysis therapy in Puglia and Lucania). Giornale Italiano di Nefrologia 19, 160-167.
62. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B & Bergstrom J (1998) Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney International 53, 773-782.
63. Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimburger O, Lindholm B & Bergstrom J (2002) Inflammation, malnutrition and cardiac disease as predictors of mortality in hemodialysis patients. Journal of the American Society of Nephrology 13, S28-S36.
64. Salahudeen AK, Dykes P & May W (2003) Risk factors for higher mortality at the highest levels of spKt/V in haemodialysis patients. Nephrology Dialysis and Transplantation 18, 1339-1344.
65. Shamsuzzaman ASM, Winnicki M, Wolk R, Svatikova A, Phillips BG, Davidson DE, Berger PB & Somers VK (2004) Independent association between plasma leptin and c-reactive protein in healthy humans. Circulation 109, 2181-2185.
66. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T & Nishizawa Y (2002) Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. Journal of the American Society of Nephrology 13, 1894-1900.
67. Sofia A, Russo R, Saffioti S, Sacco P, Dertenois L, Pastorino N, Verzola D, Ravera F, Deferrari G & Garibotto G (2002) Effetti acuti della dialisi peritoneale sul metabolismo proteico (Acute effects of peritoneal dialysis on muscle protein turnover). Giornale Italiano di Nefrologia 19, 37-43.
68. Stenvinkel P (2003) Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease. Journal of Renal Nutrition 13, 144-148.
69. Stenvinkel P & Alvestrand A (2002) Inflammation in end-stage renal disease: sources, consequences and therapy. Seminars in Dialysis 15, 329-337.
70. Stenvinkel P, Heimburger O, Lindholm B, Kaysen G & Bergstrom J (2000) Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrology Dialysis and Transplantation 15, 953-960.
71. Stenvinkel P, Heimburger O & Lonnqvist F (1997) Serum leptin concentrations correlate to plasma insulin concentrations independent of body fat content in chronic renal failure. Nephrology Dialysis and Transplantation 12, 1321-1325.
72. Stenvinkel P, Heimburger O, Tuck CH & Berglund L (1998) Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney International 53, 1336-1342.
73. Suliman ME, Heimburger O, Barany P, Anderstam B, Pecoits-Filho R, Rodriguez Ayala E, Qureshi AR, Fehrman-Ekholm I, Lindholm B & Stenvinkel P (2003) Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. Journal of the American Society of Nephrology 14, 1614-1622.
74. Szeto CC & Lai KN (1998) Metabolic acidosis and nutritional status of patients receiving continuous ambulatory peritoneal dialysis. The International Journal of Artificial Organs 21, 192-195.
75. Tonshoff B, Blum WF & Mehls O (1995) Insulin-like growth factors (IGF) and IGF binding proteins in children with chronic renal failure. Progress in Growth Factor Research 6, 481-491.
76. Tsumura M, Kinouchi T, Ono S, Nakajima T & Komoda T (2001) Serum lipid metabolism abnormalities and change in lipoprotein contents in patients with advanced-stage renal disease. Clinica Chimica Acta 314, 27-37.
77. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C & Vlassara H (2003) Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. Journal of the American Society of Nephrology 14, 728-731.
78. Vallance P, Leone A, Calver A, Collier J & Moncada S (1992) Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 339, 572-575.
79. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, et al. for the European Uremic Toxin Work Group (2003) Review on uremic toxins: classification, concentration and interindividual variability. Kidney International 63, 1934-1943.
80. Vazelov E, Borissova AM, Kirilov G, Assenova B, Tchetirska M & Krivoshiev S (2003) L-carnitine consecutively administered to patients on hemodialysis improves beta-cell response. The International Journal of Artificial Organs 26, 304-307.
81. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Boger R & CREED Investigators (2002) Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. Journal of the American Society of Nephrology 13, 490-496.
82. Zoccali C, Mallamaci F & Tripepi G (2003) Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease. Kidney International 63, Suppl. 84, S65-S68.